The report provides a detailed analysis essential for establishing a Darifenacin production plant. It encompasses all critical aspects necessary for Darifenacin production, including the cost of Darifenacin production, Darifenacin plant cost, Darifenacin production costs, and the overall Darifenacin production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Darifenacin production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Darifenacin is a prescription drug that is mainly used in the treatment of overactive bladder conditions. It is widely used in adult patients who experience bladder control problems linked to nerve or muscle activity. It is commonly prescribed to help reduce symptoms like frequent urination, sudden urges to urinate, and accidental urine leakage. It works by relaxing the bladder muscles, which allows the bladder to hold urine for a longer time. In medical practice, it supports long-term bladder management and improves the quality of life for patients with urinary disorders. It is also studied for potential application in related urological conditions where muscarinic receptor antagonism may offer therapeutic benefits. It is formulated in extended-release tablets to provide long-acting symptom relief and is recognised for its bladder-specific action, which minimises unwanted effects on other organs.
The demand for Darifenacin is primarily led by its application as an antimuscarinic agent for overactive bladder (OAB) management, which strengthens its market growth. Its application as a muscarinic receptor antagonist in the treatment of overactive bladder (OAB) to manage urinary urgency, frequency, and incontinence significantly boosts its demand in the medical sector.
Growing awareness about urinary disorders, especially among ageing populations, and the rising demand for improved quality of life further promote its market growth. Its involvement in improving bladder control and enhancing the quality of life for individuals suffering from urinary disorders further drives its demand in the healthcare sector. Technological improvements in drug delivery systems, reliable supplier networks, environmental compliance, and sustainable sourcing practices also play an important role in shaping procurement strategies across global pharmaceutical markets. Additionally, industrial Darifenacin procurement is influenced by the cost and availability of key raw materials, regulatory requirements for formulation and production, and the need for consistent quality in active pharmaceutical ingredients.
Raw Material for Darifenacin Production
According to the Darifenacin production plant project report, the major raw materials for Darifenacin production include (2S,4R)-4-hydroxy-2-pyrrolidinecarboxylic acid, 2,2 diphenylacetonitrile, 2 (2,3 dihydrobenzofuran 5 yl)acetic acid, and Hydrobromic Acid.
Production Process of Darifenacin
The extensive Darifenacin production cost report consists of the following industrial production process:
- Production via Chemical Synthesis: The production process of darfenacin hydrobromide begins with commercially available (2S,4R)-4-hydroxy-2-pyrrolidinecarboxylic acid, which undergoes thermal decarboxylation to form 3 (R)-hydroxypyrrolidine. This intermediate is N tosylated and then subjected to a Mitsunobu reaction to invert the hydroxyl group, followed by condensation with 2,2 diphenylacetonitrile to build the substituted pyrrolidine core. The tosyl protecting group is removed under acidic conditions to give the corresponding pyrrolidine salt, which is then coupled with 2 (2,3 dihydrobenzofuran 5 yl)acetic acid to form an amide. Further, the amide is reduced to the free amine, converted to its hydrobromide salt, and then hydrolysed under basic conditions to form the acetamide intermediate. After crystallisation, the final reaction with hydrobromic acid results in the formation of darfenacin hydrobromide as the finished product.
Darifenacin is a selective muscarinic M3 receptor antagonist used for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. It appears as a white to almost white crystalline powder. The molecular formula of the compound is
C28H30N2O2, and its molecular weight is 426.5 g/mol. The compound has a melting point of 228 to 230 degree Celsius and a boiling point of 614.3 degree Celsius at 760 mmHg. The compound is soluble in water at less than 1 mg per mL at 25 degree Celsius, and is also soluble in chloroform, DMSO, methanol, and ethanol. It is marketed under the brand names Enablex and Emselex. It may cause serious health problems, including severe constipation, urinary retention, blurred vision, dry mouth, heat prostration due to decreased sweating, gastrointestinal disturbances, and, in rare cases, severe allergic reactions and angioedema. It is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma, and the medication should be stored at 4 degree Celsius protected from moisture.
